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Reports on pediatric low-grade glioma (LGG) of the caudal brainstem are retrospective with heterogeneous cohorts, variable
treatments and inconsistent outcome data. We analyzed their natural history and asked whether brainstem location proved
unfavorable for survival within the framework of the comprehensive SIOP-LGG 2004 management strategy. Within the
prospectively registered, population-based German SIOP-LGG 2004 cohort 116 patients (age 0.2–16.5 years, 10%
Neurofibromatosis NF1) were diagnosed with LGG of the pons (27%) and medulla oblongata (73%). After biopsy (23%), variable
resection (63%) or radiologic diagnosis only (14%), 59 patients received no adjuvant treatment. Radiologic progression or
severe neurologic symptoms prompted chemo- (n = 39) or radiotherapy (n = 18). After further progression (28/57), salvage
treatments included multiple treatment lines for 12/28 patients. Five-years event-free survival dropped to 0.40, while 5-years
overall survival was 0.95 (median observation time 6.8 years). Higher extent of resection yielded lower progression rate
(p = 0.001), but at a cost of 21/100 patients suffering from new postsurgical complications including respiratory insufficiency.
Central review confirmed pilocytic astrocytoma (56%), diffuse astrocytoma (8%) or glioneuronal histology (16%) (others 4%, no
histology 17%). Malignant evolution was documented in five patients associated with Histone3 mutation in 2/5. Our treatment
algorithm conveyed high overall survival for pediatric brainstem LGG. Extensive neurosurgical resection did increase additional
postoperative neurologic deficits but not overall survival in this often-chronic disease. More than half of all patients can be
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safely followed by observation, while multimodal adjuvant treatment can control progressive tumors. Molecular assessment
should confirm low-grade diagnosis and may detect patterns prognostic for malignant evolution.
What’s new?
Outcome studies for pediatric low-grade gliomas (LGG) of the brainstem have generally been small and of low quality, making
it difficult to determine prognosis. In this prospective, multicenter study, the authors developed a detailed description of the
natural history, treatment response, and prognostic factors associated with favorable survival when a comprehensive
treatment strategy was used. This treatment algorithm resulted in high overall survival for pediatric brainstem LGG. The study
also emphasizes the importance of the predictive value of molecular patterns, as malignant evolution can occur even in low-
grade tumors.
Introduction
Overall survival (OS) of children and adolescents suffering
from low-grade glioma (LGG) exceeds 90% at 5 to 10 years.1,2
Still, the prognostic risk-factors determining natural biology
are not fully understood.1–5 The prognostic impact of young
age or germline mutation of neurofibromatosis type 1 (NF1)
or of tumor-related criteria like dissemination has been
defined consistently.2,6–11 However, the role of LGG location
within the central nervous system (CNS) remains controver-
sial, and this applies in particular to the caudal brainstem
where 5–10% of pediatric LGG are found. The natural course
of LGG disease is more favorable for cerebral and cerebellar
tumor location and after complete resection.3 In contrast, OS
of supratentorial midline and brainstem tumors depends on
multi-modal treatment strategies.2,8,12,13 Long-term prognosis
for brainstem LGG disease was found to be lower than for
cerebral or cerebellar sites in some cohorts.3 In larger series,
this site did not emerge as a prognostic factor after non-
surgical treatment.1,4,8 Previous reports on pediatric brainstem
LGG were confounded by including mesencephalic
tumors,14,15 or high-grade histologies.16–18 More recent series
focused on tumors exhibiting focal or dorsally exophytic
growth patterns and/or distinct low-grade histology, excluding
tumors with a diffuse intrinsic growth pattern.14,19 Survival
rates ranged from 59% to 100% at 10 years for the low-grade
tumor patients.14,16,19 So far, all reports were compiled retro-
spectively and the majority of patients had variable
treatments.
Therefore, we analyzed the natural history, response to
treatment and long-term outcome of 116 pediatric patients
with brainstem LGG included in the prospectively registered
population-based German cohort of the SIOP-LGG 2004
study when applying a comprehensive treatment strategy.
Patients and Methods
Eligibility
The prospective, multinational and multicenter SIOP-LGG
2004 study registered patients with LGG of all CNS sites from
April 1, 2004, until March 31, 2012. Inclusion criteria com-
prised age <18 years, histologic diagnosis of LGG according to
the effective WHO classification (initially 2000, later 200720),
without prior nonsurgical therapy. For brainstem location,
radiologic diagnosis was accepted, (i) if the tumor was not
amenable to surgery, and (ii) if the imaging pattern clearly
distinguished the lesion from diffuse intrinsic pontine glioma
(DIPG).21,22 Central review for pathology and radiology was
recommended.
Informed consent was obtained from patients, parents
and/or guardians. The Institutional Review Board approved
SIOP-LGG 2004 study observed the Declaration of Helsinki in
its revised version (Edinburgh, Scotland, 2000), the WHO and
European Community rules of “Good Clinical Practice” (effec-
tive 17.01.1997). The SIOP-LGG 2004 study was registered at
the ClinicalTrials.gov PRS NCT00276640 and had the
EudraCT number 2005-005377-29.
Treatment strategy
All patients with brainstem tumor location followed the gen-
eral study strategy (Supplementary Material Fig. S1): At diag-
nosis, best safe resection of the primary tumor was
recommended. Patients with complete resection were to be
observed, as well as patients after incomplete resection, biopsy
or radiological diagnosis if no threatening neurological symp-
toms were present. Severe initial symptoms or clinical or
radiological progression during observation were an indication
for the start of nonsurgical treatment, if resection remained
infeasible. Children <8 years and all children with NF1 were
to receive primary chemotherapy. Older children ≥8 years
without NF1 were allowed to receive either primary radiother-
apy (RT) or chemotherapy.1 Allocation of non-NF1 patients
≥8 years to the treatment arms was carried out at the discre-
tion of the local treatment center. The nonsurgical treatments
are termed “adjuvant” without or with prior surgical interven-
tion. Patients without indication for nonsurgical/adjuvant
treatment are termed “observed.”
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Chemotherapy
Standard chemotherapy with vincristine (V) at 1.5 mg/m2/dose
(maximum 2 mg, i.v. bolus/short-term infusion) and car-
boplatin (C) at 550 mg/m2/dose (i.v. 1-hr-infusion) was given
for 18 months (induction: 24 weeks, with 7 courses at
3–4 week intervals; consolidation: 10 courses every 6 weeks).1
For those randomized within the chemotherapy arm of the
study etoposide (E) was added with 100 mg/m2/dose (i.v. 1-hr-
infusion) on days 1–3 during induction week 1, 4, 7, and 10.1
Treatment data were recorded. Dose modifications for children
<10 kg of weight and/or <6 months of age and management of
toxicity and of hypersensitivity reactions to C were defined.1
Radiotherapy
RT was scheduled as conventional external beam radiation
with a total dose of 54 Gy (1.8 Gy per fraction). During the
study period, proton beam therapy became available for few
patients at comparable doses. Brachytherapy/interstitial radio-
surgery for suitable tumors was applied with 125-Iodine-
seeds.23
Radiologic follow-up
Contrast-enhanced MRI was regularly performed at defined
intervals in all patients and was planned at week 24, 54 and
85 after the start of adjuvant therapy for response assessment.
Complete, partial and objective responses (regression) as well
as stable disease (SD) were considered positive responses.1,24
Salvage treatment
Treatment for progression after primary radio- or chemother-
apy was not standardized, but included all modalities after dis-
cussion in local and reference tumor boards.
Statistics
For continuous variables, median and range are given. Categorical
variables are indicated in absolute or relative frequencies.
The distribution of OS, progression-free survival (PFS) and
event-free survival (EFS) were estimated with the Kaplan-Meier
method and compared between independent groups using log-
rank test. OS was calculated from date of diagnosis until death
(of any cause). To evaluate OS in the chemotherapy and RT
subgroups, OS was in derogation thereof calculated from start
of therapy until death (of any cause). EFS was calculated from
date of diagnosis until event, defined as relapse after complete
resection, clinical or radiological progression, start of non-
surgical/adjuvant therapy or death of any cause. To evaluate
the variables resection and histology, EFS was in derogation
thereof calculated from the date of surgery until event. PFS was
calculated from the start of nonsurgical/adjuvant therapy until
event, defined as relapse after complete remission, clinical or
radiological progression or death of any cause.
Cox regression with forward stepwise selection (inclusion
criterion: score test p ≤ 0.05; exclusion criterion: likelihood
ratio test p > 0.10) was used to analyze the prognostic value of
clinical and biologic variables on EFS. Variables included age
(years) at diagnosis (≤1 year, >1 to <8 years, ≥8 years), sex,
NF1-status, localization (pons vs. medulla oblongata), dissemi-
nation, extent of resection and histology (pilocytic astrocy-
toma [PA] vs. diffuse astrocytoma vs. glioneuronal tumors).
Extent of resection and histology were included as time-
dependent variables for EFS from the date of surgery.
Analyses were exploratory, and p-values were considered
as descriptive measures to detect and study meaningful effects.
In particular, no significance level was defined.
Data availability
The data sets generated during and/or analyzed during the
current study are available from the corresponding author on
reasonable request.
Results
Cohort description
Brainstem tumor location was stated for 120 of 1,586 regis-
tered patients from the German SIOP-LGG 2004 cohort
(77 participating hospitals). Four patients were excluded upon
review for diagnosis (n = 1 DIPG, n = 1 Alexander disease) or
tumor location (n = 2, primary cerebellar site with brainstem
involvement) (Fig. 1). Detailed data for the 116 patients of this
report are given in Table 1. Median age at diagnosis was
5.6 years with a clear male preponderance (m:f ratio 1.6:1).
NF1 was diagnosed clinically and/or genetically in 12 patients.
Only a quarter of tumors originated in the pons (27%), while
the majority emerged from the medulla (73%), more than half
of the tumors from both sites extended into neighboring
structures; for 7 patients primary (n = 4) or secondary (n = 3)
dissemination was reported. Central radiologic review of
sequential MRIs was performed for 110 patients.
At the time of diagnosis, 106/116 symptomatic patients
(5/12 NF1) suffered from single (31/106) or combined
(75/106) symptoms related to tumor site. Still, brainstem LGG
was an incidental finding in 10 patients (9%, follow-up of sur-
gery for synostosis, imaging for NF1 [4/12], trauma or tics).
Besides long-tract signs (n = 47) or cranial nerve palsy
(n = 63), increased intracranial pressure (n = 12) and ataxia
(n = 10), functional symptoms like newly developed torticollis
(n = 31) or isolated vomiting (n = 27) were frequent. No
patient presented with the triad of simultaneous long-tract
signs, cranial nerve palsies and ataxia.
Surgery
At least one neurosurgical intervention was performed in
100/116 patients (Table 1). Eighteen patients underwent sev-
eral subsequent resections and biopsies. Twenty-one patients
developed significant new postoperative neurologic impair-
ments, including respiratory insufficiency in 5, postoperative
cerebellar mutism in 3, and cranial nerve palsy, hemi- or
tetra-paresis in 15 patients. Deficits were observed in only 4%
of the patients who underwent biopsy (n = 1/27), while they
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occurred in 38% (n = 5/13), 46% (n = 6/13) and 19%
(n = 9/47) after initial complete, subtotal or partial resection.
Deficits persisted in 18/20 survivors. There were no surgery-
associated deaths.
Histologic diagnosis
LGG histology was confirmed upon central review for 96 tumors.
In four cases, limited biopsy tissue impeded LGG diagnosis
(n = 2) or the sample did not contain tumor tissue (n = 2). Thus,
in 20 patients (17%) the diagnosis of LGG relied upon centrally
confirmed radiologic criteria. The majority of tumors were PA
WHO Grade I. One had a pilomyxoid pattern. Glioneuronal
tumors constituted the second largest group and nine tumors
were classified as diffuse astrocytoma WHO Grade II. Molecular
tumor assessment was performed in 17/96 cases (Table 1):
KIAA1549-BRAF-fusion was found in 3 PA, 1 ganglioglioma
and 1 diffuse astrocytoma, whereas BRAF-V600E mutation was
found in 1 ganglioglioma only. Histone3-K27M mutation was
seen in 2 diffuse astrocytomas; another 4 diffuse astrocytomas
revealed BRAF/IDH/Histone3-wild type.
Strategic subgroups
During the study period (median follow-up 6.8 years)
59 patients without (n = 11) or with neurosurgical interven-
tion (n = 48) did not receive adjuvant treatment, while
57 patients needed adjuvant treatment (Fig. 1).
Patients remaining observed: during the study period
11/59 patients without adjuvant treatment suffered from
tumor progression after initial complete (2/12), subtotal
(2/11), and partial resection (5/18) or radiologically diagnosed
brainstem LGG (2/11). Tumor growth ceased spontaneously
in 5/11; and 2/11 achieved SD after 1–2 re-resections.
Three/11 patients had further progression despite surgery,
information is missing for one. At last follow-up, 50/59
patients are alive, 3 patients had deceased (1 after tumor-
associated respiratory dysregulation, 1 after continuous pro-
gression despite multiple resections, 1 with the malignant
relapse of a diffuse astrocytoma wild type for BRAF/IDH/His-
tone3 mutation at retrospective analysis). Six patients were
lost to follow-up.
Patients without need for adjuvant treatment within the
first three years after diagnosis tended to be older at diagnosis,
had more often initial complete/subtotal resection or radio-
logic diagnosis, and their tumor histology was more often
glioneuronal as compared to their counterparts.
Chemotherapy group: primary adjuvant treatment was
chemotherapy for 39 patients starting at a median age of
5.7 years. None of them had an initial complete or subtotal
tumor resection. Treatment with VC (n = 31) or VCE (n = 8)
commenced following a median observation time of 0.7 years
for the presence of severe neurologic symptoms in 48%
(19/39), radiologic progression in 31% (12/39) and the combi-
nation of both in 21% (8/39). Chemotherapy was well toler-
ated; switching to alternative consolidation was necessary in
14 patients due to C hypersensitivity reactions. Radiologic
response after induction at week 24 was tumor regression and
Figure 1. Brainstem LGG cohort. Patient numbers and distribution among strategic subgroups.
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Table 1. Epidemiologic data
Patients characteristic All patients n = 116 Chemotherapy n = 39 Radiotherapy n = 18
Median age (years, range)
At diagnosis 5.6 (0.2–16.5) 3.5 (0.2–12.7) 8.1 (0.8–13.6)
At start of therapy – 5.7 (0.5–15.3) 10.8 (1.2–17.9)
Median interval from diagnosis to start of
treatment (years, range)
– 0.7 (0.0–5.9) 1.8 (0.1–7.0)
Age group
≤1 year 5 (4.3%) 3 (7.7%) 1 (5.6%)
>1 to <8 years 68 (58.6%) 31 (79.5%) 7 (38.9%)
≥8 years 43 (37.1%) 5 (12.8%) 10 (55.6%)
Sex
Male 72 (62.1%) 23 (59.0%) 12 (66.7%)
Female 44 (37.9%) 16 (41.0%) 6 (33.3%)
NF1 status
NF1 12 (10.3%) 8 (20.5%) –
Non-NF1 103 (88.8%) 30 (76.9%) 18 (100%)
Not known 1 (0.9%) 1 (2.6%) –
Localization
Pons 31 (26.7%) 9 (23.0%) 7 (38.9%)
Medulla oblongata 85 (73.3%) 30 (77.0%) 11 (61.1%)
Local tumor extension
No extension beyond origin 52 (44.8%) 16 (41.0%) 9 (50.0%)
Dorsal extension 23 (19.8%) 11 (28.2%) 7 (38.8%)
Caudal extension 22 (19.0%) 5 (12.8%) 1 (5.6%)
Cranial extension 14 (12.1%) 3 (7.7%) 1 (5.6%)
Dorsal and caudal extension 1 (0.9%) 1 (2.6%) –
Dorsal and cranial extension 3 (2.6%) 3 (7.7%) –
Cranial and caudal extension 1 (0.9%) – –
Dissemination
No 109 (94.0%) 34 (87.2%) –
Yes 7 (6.0%) 5 (12.8%) –
Primary surgery
Complete resection 13 (11.2%) – 1 (5.6%)
Subtotal resection 13 (11.2%) – 2 (11.1%)
Partial resection 47 (40.5%) (1 NF1) 20 (51.3%) 9 (50.0%)
Open biopsy 14 (12.1%) (1 NF1) 9 (23.0%) 1 (5.6%)
Stereotactic biopsy 13 (11.2%) (3 NF1) 6 (15.4%) 4 (22.2%)
No surgery2 16 (13.8%) (7 NF1) 4 (10.3%) 1 (5.6%)
Histology
Pilocytic astrocytoma I1 65 (56.0%) 23 (59.0%) 13 (72.2%)
Pilomyxoid astrocytoma II 1 (0.9%) 1 (2.5%) –
Diffuse astrocytoma II1 9 (7.6%) 4 (10.3%) 2 (11.1%)
Glioneuronal tumors 18 (15.5%) 4 (10.3%) 2 (11.1%)
Ganglioglioma I1 16 3 2
DIG/DIA 2 1 –
Other histologies 3 (2.6%) 2 (5.1%) –
Astrocytoma NOS 2 1 –
LGG NOS 1 1 –
No histology2 20 (17.2%) 5 (12.8%) 1 (5.6%)
(Continues)
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SD in 12 and 19, respectively, of 37 evaluable patients (84%
combined response), while 6/37 showed progressive disease
(16%). Two patients had no radiologic assessment at this time
point. Further 18 patients developed progression during con-
solidation (n = 7) or surveillance (n = 11). Salvage treatment
for these 24 progressing tumor patients included one further
treatment modality in six patients (proton RT [n = 2], photon
RT [n = 3], chemotherapy [n = 1]). Multiple further treatment
lines for successive progressions were given in 10 patients
combining re-resection plus second chemotherapy (n = 1) or
proton RT (n = 2) or ≥2 adjuvant treatments without or with
further resection(s) (n = 7, 2/7 photon RT). Eight of
24 patients had no further adjuvant treatment, but partial re-
section in 4 and spontaneous switch to SD in 3. One of
24 patients died during first-line chemotherapy from rapidly
progressing tumor. At the last follow-up, 32 patients were
alive and 6 patients had died. In one of them, astrocytoma
WHO Grade III had been diagnosed at last biopsy, in another
patient suffering from reference-confirmed diffuse astrocy-
toma retrospective analysis disclosed Histone3-K27M muta-
tion. One patient was lost to follow-up.
RT group: primary adjuvant treatment was RT for
18 patients starting at a median age of 8.7 years, following a
median observation time of 1.8 years, due to severe neurologic
symptoms in 11% (2/18), radiologic progression/relapse in 67%
(12/18) and the combination of both in 17% (3/18) (1 not docu-
mented). External fractionated RT with protons (n = 1) or pho-
tons (n = 11) was given at a median dose of 54 Gy
(48.4–59 Gy). Six tumors were suitable for interstitial radiosur-
gery. Tumor response at week 24 was regression and SD in
9 and 4 of 15 evaluable patients, respectively (87%). Two tumors
progressed: one tumor exhibited malignant histology at partial
resection (ganglioglioma WHO Grade III, BRAF-V600E-
mutated), 70 months after initial diagnosis of ganglioglioma
WHO Grade I. After chemotherapy with temozolomide, this
patient achieved SD. The other tumor met criteria of a highly
amino-acid avid tumor at FET-PET assessment (O-(2-[18F]
fluoroethyl)-L-tyrosine-PET), progressed rapidly despite further
chemotherapy and eventually the patient died. Histone3-K27M
mutation was proven retrospectively in this diffuse astrocytoma.
Three patients had no radiologic assessment at Week 24.
Another 2 tumors progressed 85 weeks and 5 years after the
start of RT; complete remission was achieved after multiple
resections and chemotherapy in both. At the last follow-up,
16 patients were alive (1 lost to follow-up).
In summary, 27 patients received RT as primary or salvage
(n = 9) treatment.
Survival data
Survival data, including the results of exploratory univariable
analyses, are detailed in Table 2 and illustrated in Figures 2a,
2b and 3a–3d. OS for the entire cohort was 0.95 (0.02) at
5 and 0.86 (0.05) at 10 years. Five-years OS was 0.89
(0.05) for the chemotherapy and 0.94 (0.05) for the RT
group. Five-years EFS for the entire cohort was 0.40 (0.05).
It was better for patients older than 8 years, after complete/
subtotal resection, without dissemination or for tumors of
glioneuronal histology. Multivariable analysis confirmed these
characteristics as independent determining factors for EFS
(Table 3). Five-years PFS after first adjuvant treatment was
Table 1. Epidemiologic data (Continued)
Patients characteristic All patients n = 116 Chemotherapy n = 39 Radiotherapy n = 18
Observation time from diagnosis to last follow-up
(years, range)
6.8 (0.6–15.0) 7.3 (0.7–14.1) 7.8 (0.6–15.0)
Status at last follow-up
Alive 98 32 16
Without tumor 15 1 5
With stable tumor 80 30 10
With progressive tumor 2 1 –
Evolution of HGG 1 – 1
Lost to follow-up 8 1 1
Status at last follow-up 5CR/SD,2PD,1nn 1PD 1nn
Dead 10 6 1
Tumor progression 5 4 –
Complication3 1 – –
Evolution of HGG 4 2 1
1Molecular data from residual tumor tissue available for 8/65 pilocytic astrocytomas (3 KIAA1549-BRAF-fusion, 1 NF1 with CDKN2A mutation, 4 wild
type for BRAF/IDH mutation), 7/9 diffuse astrocytomas (2 Histone3-K27M mutation, 1 KIAA1549-BRAF-fusion, 4 wild type for BRAF/IDH/Histone3 muta-
tion) and 2/16 gangliogliomas (1 KIAA1549-BRAF-fusion, 1 BRAF-V600E mutation).
2Four patients with biopsy (3 stereotactic, 1 open) but no meaningful histology.
3Tumor-associated respiratory dysregulation.
Abbreviations: DIA, desmoplastic infantile astrocytoma; DIG, desmoplastic infantile ganglioglioma; HGG, high-grade glioma; nn, not known; NOS, not
otherwise specified.
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0.42 (0.08) after chemotherapy and 0.83 (0.09) after
RT. Exclusion of cases with Histone3-mutated tumors and of
all cases with malignant evolution did not alter OS, EFS or
PFS (Table 2).
Discussion
Our treatment algorithm conveyed high OS and PFS for this
prospectively registered cohort with pediatric brainstem LGG
comparable to results for other CNS sites. Extensive
neurosurgical resection did increase additional postoperative
neurologic deficits but not OS in this often-chronic disease.
More than half of all patients can be safely followed by observa-
tion, while multimodal adjuvant treatment can control progres-
sive tumors despite frequent progressions.
Our cohort is comparable to other series with LGG of all
locations2,8 or of brainstem only14,15,19 with respect to age, sex
ratio and portion of NF1. While the dominant location within
the caudal brainstem was either pontine14,15 or medullary16,25
Table 2. Results of univariable survival analysis: 5-year overall survival (OS), 5-year event-free survival and 5-year progression-free survival by
subgroups
All patients n = 116 Chemotherapy1 n = 39 Radiotherapy1 n = 18
Overall survival
All 0.95 (0.02) 0.89 (0.05) 0.94 (0.05)
Histone3 mutations excluded 0.96 (0.02) 0.92 (0.05) 1.00
Malignant histologies excluded 0.96 (0.02) 0.92 (0.05) 1.00
Event-free survival
All 0.40 (0.05) – –
Histone3 mutations excluded 0.41 (0.05) – –
Malignant histologies excluded 0.42 (0.05) – –
Age p = 0.021 – –
≤1 year 0.20 (0.18)
>1–<8 years 0.33 (0.06)
≥8 years 0.55 (0.08)
Sex p = 0.061 – –
Male 0.48 (0.06)
Female 0.28 (0.07)
NF1 p = 0.095 – –
Present 0.25 (0.13)
Not present 0.42 (0.05)
Localization p = 0.216 – –
Pons 0.29 (0.09)
Medulla oblongata 0.44 (0.06)
Extent of resection2 p < 0.001 – –
Complete 0.76 (0.12)
Subtotal 0.67 (0.14)
Partial 0.29 (0.07)
Biopsy 0.29 (0.09)
Histology2 p = 0.007 – –
Pilocytic astrocytoma 0.36 (0.06)
Diffuse astrocytoma 0.14 (0.13)
Glioneuronal tumors 0.61 (0.12)
Dissemination p = 0.046 – –
Present 0.00
Not present 0.43 (0.05)
Progression-free survival
All – 0.42 (0.08) 0.83 (0.09)
Histone3 mutations excluded – 0.43 (0.08) 0.88 (0.08)
Malignant histologies excluded – 0.44 (0.08) 0.87 (0.09)
1In chemotherapy/radiotherapy subgroups: 5-year OS measured from start of therapy.
2Five-year EFS measured from the date of surgery.
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in small, not population-based reports, our series confirms
that three quarters of brainstem LGG reside in the medulla
oblongata, and that more than half of all brainstem tumors
extend into neighboring structures clearly limiting attempts of
radical resection. As opposed to DIPG the triad of long-tract
signs, cranial nerve palsy and ataxia was not present in our
patients.26 Still, 70% had combined symptoms at diagnosis.
Being an early symptom for posterior fossa tumors,27 the high
frequency of torticollis in more than 25% of our patients was
not described previously highlighting the necessity of neuro-
imaging in these patients.28 We attribute the lower frequency
of hydrocephalus in our cohort as compared to the series of
Klimo et al.14 and Sandri et al.17 to the exclusion of mesence-
phalic tumors where aqueduct obstruction causes symptoms
of increased cranial pressure in more than 80%.12
Impact of surgery
For all LGG, surgery tends to be the first procedure. Tumor
resection is generally accepted as “treatment of choice,”
including second interventions or treatment of local
relapse.3,8,29 Anatomical site determines resectability, which,
in turn, when complete, is associated with better survival out-
comes in both low- and high-grade glioma.29 Improvement of
surgical techniques, use of intraoperative adjuncts, especially
neurophysiological monitoring, and referral to specialized
pediatric neurosurgical centers contributed to reduced postop-
erative morbidity after resection for brainstem LGG.18,30,31
Complete and subtotal resection rates of 16–53% and 24–56%,
respectively, were reported in small monocentric series,14,18,19
but were clearly lower in our cohort with 10% and 16%,
respectively. Corroborating the low risk for relapse after
complete resection in the series from Pollack et al.32 and
Upadhyaya et al.,19 only 3/13 completely resected LGG within
our cohort relapsed. However, the risk to damage critical
structures upon resection of a brainstem tumor is high31–33
and critically reflected by a 21% rate of severe postoperative
complications being more relevant in complete/subtotal (46%)
and less in partial resection (19%) or biopsy (4%) within this
protocol. Referral to specialist pediatric centers for brainstem
interventions and detailed multidisciplinary team discussion
are the most pertinent requests to reduce operative morbidity
with its lifelong burden for patients and families in this often-
chronic disease.29
Impact of histologic confirmation
Nevertheless, confirmation of LGG-histology is warranted and
was obtained for 83% tumors within our cohort. Several his-
toric series of pediatric brainstem tumors included low- and
high-grade histologies16–18 and do not allow drawing conclu-
sions about efficacy of treatment for the low-grade cases or
analyzing risk factors. On the other hand, radiologic diagnosis
was broadly accepted for LGG in the past, especially for
NF1-associated tumors of the visual pathways,34 and radio-
logic criteria to discriminate DIPG from LGG were
established.21,22 Within our cohort, more than a third of those
with radiologic diagnosis were NF1-patients for whom radio-
logic diagnosis of brainstem LGG has been accepted.35 Two-
thirds of the histologies were PA, and glioneuronal tumors
had a share of 20% comparable to other series.19 The intro-
duction of molecular assessment during the latter part of the
study allowed additional confirmation of diagnosis in several
cases. Detection of the KIAA1549-BRAF fusion was possible
Figure 2. Overall, event-free and progression-free survival. (a) OS and EFS for the entire group. (b) OS and PFS for the chemotherapy and
radiotherapy groups.
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in two specimens strengthening the most probable diagnosis
of a LGG. In the report of Upadhyaya et al.,19 retrospectively
analyzed tissue confirmed KIAA1549-BRAF-fusion in four of
seven cases with ganglioglioma and PA, none was BRAF-
V600E positive. However, molecular assessment is most
imperative in ruling out high-grade histologic features. For
two tumors with previous centrally confirmed astrocytoma
WHO Grade II, we identified presence of Histone3-K27M
mutation, characteristic for diffuse midline glioma.36 Histone3
mutations have been described in low-grade thalamic and
brainstem tumors,37,38 preceding malignant evolution.39 Since
almost all of these patients eventually die,38,40 we question the
maintenance of the term “low-grade” for these tumors. Yet,
their exclusion from survival analysis did not affect OS,
underpinning the favorable outcome of this cohort. Malignant
progression was additionally seen in three other patients. For
those latter patients it is not clear, whether current molecular
diagnosis would have revealed relevant mutations. Yet, the rel-
evant frequency of malignant evolution underlines the need
for histologic and molecular confirmation of presumably low-
grade brainstem lesions; repeat tissue diagnosis is warranted
at relapse or unexpected evolution.41 Stereotactic biopsy is
adequate provided sufficient material for detailed analysis can
be obtained.42
Consequences of patient stratification
Current approaches to adjuvant treatment of LGG in children
and adolescents emphasize that there are no apparent differ-
ences in long-term OS after immediate post-operative versus
delayed onset of RT or chemotherapy,43,44 and relate the
choice of the primary adjuvant treatment modality to age,
tumor location and size and the time point during the course
Figure 3. Event-free survival for noticeable prognostic factors. (a) EFS for age. (b) EFS for extent of resection. (c) EFS for histology. (d) EFS for
dissemination.
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of the disease.1,4,43,45 After the comprehensive treatment algo-
rithm of the SIOP-LGG 2004 study, only 16 of our patients
had an indication to start adjuvant treatment at the time of
diagnosis, while the majority was initially observed. Over time,
many patients, especially if younger at diagnosis, progressed
clinically and/or radiologically, resulting in a drop of 5-year
EFS to 40%. Events occurred without noticeable differences
between primary pontine and medullary site, while a lesser
extent of initial resection and astrocytic histology were associ-
ated with a clearly higher progression rate, discrepantly dis-
cussed in previous reports.14,15,17,19 But either spontaneous
deceleration of tumor growth-rate or neurosurgical re-
interventions allowed retaining a further “wait-and-see” con-
duct for half of our cohort. The higher risk of progression for
infants has been uniformly described in various LGG
series.1,2,9,11
Chemo- and RT: adjuvant treatment started upon defined
indications only,1 and the same principles applied to the man-
agement of subsequent progression. For none of the retrospec-
tive series, a standardized approach for the initiation of radio-
or chemotherapy is detailed14–19,25,31 impeding the direct
comparison of treatment results. In the series of Upadhyaya
et al.,19 only 9/25 patients did not receive adjuvant radio- or
chemotherapy after successive progressions. In the majority of
reports, most patients had primary RT14–17,19; few patients
were treated with various chemotherapy regimens.14,16,17,19
The efficacy of V/C for brainstem LGG had been confirmed
by Ronghe et al. in a series of 16 patients.46 The favorable out-
come of our treatment groups with a 5-year OS 89% and 94%
after primary chemotherapy and RT, respectively, underscores
the appropriateness of the study strategy for pediatric
brainstem LGG. Furthermore, primary RT was delayed to a
median age above 8 years in the cohort of 18 patients, and in
total only a quarter of all patients had focal irradiation during
the course of treatment. Limited by small numbers and being
embedded in treatment successions, the relative efficacy of
protons, photons and interstitial radiosurgery is difficult to
determine. Nevertheless, 22/27 patients irradiated at some
point of their treatment course achieved CR and SD. Since
early radiation was associated with death mainly attributed to
late malignant transformation of primary tumors on long-
term follow-up of pediatric LGG patients,47,48 primary stan-
dard chemotherapy is warranted for brainstem LGG.
Reflecting stratification within the SIOP-LGG 2004 treatment
algorithm median age in the chemotherapy group was lower
and young patients needed treatment earlier than in the RT
group. Despite a high response rate at Week 24 of 84% of
tumors (regression plus SD), the chemotherapy-first strategy
came with a 5-year PFS of 42% only compared to 83% for the
RT group. As a consequence, primary chemotherapy was
associated with multiple lines of treatment for 61% of patients,
but this did not compromise survival. No late RT-induced
malignancies were observed so far.
Neurofibromatosis: only a smaller fraction of brainstem
glioma in NF1-patients was symptomatic and/or progressive
and needed treatment in a multi-institutional series.35 Since
the risk for RT-induced late effects is highly increased in NF1,
chemotherapy is currently recommended to avoid up-front as
well as salvage RT.49 Eight of our 12 NF1 patients received
chemotherapy at tumor progression; none was irradiated and
all survived. It cannot be ruled out that referral bias for symp-
tomatic NF1-patients, who otherwise are followed in neuro-
pediatric services, accounts for the higher percentage of treat-
ment indications as compared to the series of Mahdi et al.35
Functional outcome
Despite detailed documentation of the clinical course of our
patients, we lack standardized neurologic assessments during
follow-up to complement the radiologic tumor status. While
27/106 survivors reported no neurologic sequelae and we lack
information in 9/106, a load of symptoms is reported for the
remaining 70/106 patients, among them persistence of long-
tract signs (n = 25/70), cranial nerve palsy (n = 41/70), ataxia
(n = 30/70), respiratory insufficiency (n = 8/70), difficulties of
swallowing (n = 10/70) or speech (n = 5/70). Since most of
our pediatric patients have to accept a lifelong impact of their
Table 3. Multivariable analysis of event-free survival
Predictors HR 95% CI p value
Age 0.046
≤1 year vs. ≥8 years (ref.) 5.68 (1.71–18.92)
>1 to <8 years vs. ≥8 years
(ref.)
1.31 (0.69–2.51)
Sex N/S: 0.380
Female vs. male (ref.) – –
NF1 0.079
Present vs. not present
(ref.)
2.95 (0.97–9.00)
Localization N/S: 0.172
Pons vs. Medulla
oblongata (ref.)
– –
Extent of resection1 <0.001
Subtotal vs. complete
(ref.)
1.25 (0.26–5.91)
Partial vs. complete (ref.) 4.91 (1.39–17.34)
Biopsy vs. complete (ref.) 15.27 (3.91–59.59)
Histology1 <0.001
Diffuse astrocytoma vs.
pilocytic astrocytoma
(ref.)
3.21 (1.14–9.06)
Glioneuronal tumors vs.
pilocytic astrocytoma
(ref.)
0.23 (0.09–0.59)
Dissemination 0.009
Present vs. not present
(ref.)
4.08 (1.60–10.38)
1Treated as time-dependent variable that becomes known at the date of
surgery.
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brainstem LGG upon brain function, future studies should
include functional outcome endpoints.50
Conclusion
Our data confirm favorable OS for children and adolescents
with LGG of the caudal brainstem within the population-
based prospective SIOP-LGG 2004 comprehensive treatment
strategy. Although EFS is better after more extensive neuro-
surgical interventions, the extent of resection should be care-
fully chosen to avoid additional postoperative deficits, and
referral to multidisciplinary pediatric neuro-oncology teams is
recommended. Even with a high portion of incompletely
resected tumors, more than half of the patients in our
population-based series can be followed by observation, while
the multimodal treatment strategy, including multiple treat-
ment lines, allows controlling even progressive tumors. Radio-
logic diagnosis of a LGG should be reserved for exceptional
cases. We recommend tissue-based histologic and molecular
diagnosis for all tumors. Research is needed to detect reliable
patterns predictive of possible malignant evolution.
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